IP Library Granted Patent US 11,155,804
Granted Patent B2
US 11,155,804 · App. 16/316,768 · Granted Oct 26, 2021

Recombinant polypeptides comprising selenocysteine and method for producing the same

Inventors: Andrew D. Ellington (Austin, TX); Ross Thyer (Austin, TX)
Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
C12N9/86C07H21/02C12N15/11A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,804
App. No.
16/316,768
Granted
Oct 26, 2021
Kind
B2
Abstract

Composition comprising purified recombinant selenoproteins, such an antibodies and enzymes, are provided. Method of producing such recombinant polypeptides and bacterial strains for the same are likewise provided.

Claims (40)

1. A nucleic acid molecule encoding a polypeptide comprising an amino acid sequence at least 90% identical to:

(a) SEQ ID NO:1 and having an amino acid substitution or deletion at a position corresponding to position 344 of SEQ ID NO:1;

(b) SEQ ID NO:2 and having an amino acid substitution or deletion at a position corresponding to position 702 of SEQ ID NO:2;

(c) SEQ ID NO:3 and having an amino acid substitution or deletion at a position corresponding to position 655 of SEQ ID NO:3;

(d) SEQ ID NO:4 and having an amino acid substitution or deletion at a position corresponding to position 73 of SEQ ID NO:4;

(e) SEQ ID NO:5 and having an amino acid substitution or deletion at a position corresponding to position 781 of SEQ ID NO:5;

(f) SEQ ID NO:6 and having an amino acid substitution or deletion at a position corresponding to position 136 of SEQ ID NO:6;

(g) SEQ ID NO:7 and having an amino acid substitution or deletion at a position corresponding to position 183 of SEQ ID NO:7;

(h) SEQ ID NO:8 and having an amino acid substitution or deletion at a position corresponding to position 1 of SEQ ID NO:8;

(i) SEQ ID NO:9 and having an amino acid substitution or deletion at a position corresponding to position 102 of SEQ ID NO:9;

(j) SEQ ID NO:10 and having an amino acid substitution or deletion at a position corresponding to position 105 of SEQ ID NO:10;

(k) SEQ ID NO:11 and having an amino acid substitution or deletion at a position corresponding to position 673 of SEQ ID NO:11;

(l) SEQ ID NO:12 and having an amino acid substitution or deletion at a position corresponding to position 69 of SEQ ID NO:12;

(m) SEQ ID NO:13 and having an amino acid substitution or deletion at a position corresponding to position 107 of SEQ ID NO:13;

(n) SEQ ID NO:17 and having an amino acid substitution or deletion at a position corresponding to position 246 of SEQ ID NO:17;

(o) SEQ ID NO:18 and having an amino acid substitution or deletion at a position corresponding to position 545 of SEQ ID NO:18; and/or

(p) SEQ ID NO:19 and having an amino acid substitution or deletion at a position corresponding to position 124 of SEQ ID NO:19.

2. A bacterial strain comprising at least one nucleic acid molecule selected from claim 1 .

3. The bacterial strain of claim 2 , wherein the bacterial strain is an E. coli strain.

4. The bacterial strain of claim 2 , comprising a nucleic acid that encodes a tRNA that is at least 90% identical to SEQ ID NO: 20 and comprising one or more of the following features:

(i) a G or C at a position corresponding to position 7;

(ii) a T at a position corresponding to position 49;

(iii) a A or C at a position corresponding to position 50;

(iv) a T at a position corresponding to position 64;

(v) a G or A at a position corresponding to position 65; and/or

(vi) a G, T or C at a position corresponding to position 66.

5. The bacterial strain of claim 4 , wherein the molecule encodes a tRNA comprising the sequence at least about 90% identical to SEQ ID NO: 20; and comprises one or more of the following features:

(i) a G at a position corresponding to position 7;

(ii) a T at a position corresponding to position 49;

(iii) a C at a position corresponding to position 50;

(iv) a T at a position corresponding to position 64;

(v) a G at a position corresponding to position 65; and/or

(vi) a C at a position corresponding to position 66.

6. The bacterial strain of claim 3 , wherein the strain is the E. coli bacterial strain deposited at the NCIMB under deposit Accession No. 42595.

7. A culture of bacteria comprising a bacterial strain in accordance with claim 2 .

8. The culture of claim 7 , said culture comprising an expressed recombinant polypeptide in an amount of 1 to 100 mg/L of the culture, said expressed recombinant polypeptide comprising at least one selenocysteine residue.

9. The culture of claim 8 , comprising an expressed recombinant polypeptide in an amount of 10 to 40 mg/L of the culture, said expressed recombinant polypeptide comprising at least one selenocysteine residue.

10. A method of expressing a polypeptide comprising at least one selenocysteine residue comprising:

(a) expressing a nucleic acid encoding the polypeptide in a bacterial strain according to claim 2 and in the presence of selenium source; and

(b) purifying the recombinant polypeptide from the bacteria.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2019
From: ELLINGTON, ANDREW D.; THYER, ROSS
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 050323/0216 →
CONFIRMATORY LICENSE Recorded Mar 11, 2019
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 048560/0895 →
Continuity (2)
Provisional Application 62360745 · Jul 11, 2016
Related Publication 20190316110A1 · Oct 17, 2019